Cargando...

Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571

The Bcr-abl kinase inhibitor STI571 produces clinical responses in most patients with Chronic Myeloid Leukemia (CML); however, development of resistance limits utility. One strategy to overcome STI571 resistance is to decrease the level/activity of Bcr-abl. We reported that disruption of the anti-ap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wang, Zhanxiang, Pelus, Louis M.
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2600525/
https://ncbi.nlm.nih.gov/pubmed/19079792
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!